Mónica Musteanu

Universidad Complutense de Madrid — Spain

Medicine · Health Sciences

20h-index1.8kcitations74works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(26), Radiomics and Machine Learning in Medical Imaging(14), Melanoma and MAPK Pathways(13), Medical Imaging Techniques and Applications(12), Lung Cancer Treatments and Mutations(10)

Publications74 total

A disease model resource reveals core principles of tissue-specific cancer evolution
Nature·2026Open Access
RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1
PLoS ONE·2026Open Access
A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance
Proceedings of the National Academy of Sciences·2025· 3 citedOpen Access
The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations
EMBO Molecular Medicine·2025Open Access
Systemic <i>Kras</i> ablation disrupts myeloid cell homeostasis in adult mice
Proceedings of the National Academy of Sciences·2025· 3 citedOpen Access
A TARGETED COMBINATION THERAPY ACHIEVES EFFECTIVE PANCREATIC CANCER REGRESSION AND PREVENTS TUMOR RESISTANCE
2025· 2 citedOpen Access
Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors
Proceedings of the National Academy of Sciences·2024· 10 citedOpen Access
CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis
Cancer Letters·2024· 8 citedOpen Access
CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel driver of metastasis in prostate cancer
2023Open Access
CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel driver of metastasis in prostate cancer
2023Open Access
Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity
Cell·2023· 158 cited
Abstract B025: The RAF/MEK clamp avutometinib (VS-6766) enhances antitumor efficacy of KRAS G12C and G12D inhibitors through vertical inhibition of RAS, RAF and MEK. &amp;lt;/title&amp;gt;
Molecular Cancer Research·2023· 2 cited
Abstract 5992: Cells rapidly adapt to CDK2 inhibitors via plasticity of the CDK2/4/6-Rb-E2F axis
Cancer Research·2023· 2 cited
Table S4 from SPARC Expression Did Not Predict Efficacy of &lt;i&gt;nab&lt;/i&gt;-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Figure S1 from SPARC Expression Did Not Predict Efficacy of &lt;i&gt;nab&lt;/i&gt;-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Table S3 from SPARC Expression Did Not Predict Efficacy of &lt;i&gt;nab&lt;/i&gt;-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Figure S2 from SPARC Expression Did Not Predict Efficacy of &lt;i&gt;nab&lt;/i&gt;-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Table S5 from SPARC Expression Did Not Predict Efficacy of &lt;i&gt;nab&lt;/i&gt;-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Table S4 from SPARC Expression Did Not Predict Efficacy of &lt;i&gt;nab&lt;/i&gt;-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
Table S1 from SPARC Expression Did Not Predict Efficacy of &lt;i&gt;nab&lt;/i&gt;-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Mariano Barbacid(22), Emilio Casanova(14), Robert Eferl(14), Carmen Guerra(13), Matthias Drosten(12), Manuel Hidalgo(11), Leander Blaas(11), Pedro P. López‐Casas(10), Carmen G. Lechuga(9), Manuel Sanclemente(8), Valeria Poli(7), Eduardo Caleiras(7), Carlos Plaza(6), Fernando López‐Ríos(6), Lukas Kenner(6), Beatrice Grabner(6), Alejandra López-García(6), Laura Esteban-Burgos(5), Lucía Morales-Cacho(5), Fernando Fernández-García(5)